» Articles » PMID: 34573112

Oxidative Stress and Beta Amyloid in Alzheimer's Disease. Which Comes First: The Chicken or the Egg?

Overview
Date 2021 Sep 28
PMID 34573112
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

The pathogenesis of Alzheimer's disease involves β amyloid (Aβ) accumulation known to induce synaptic dysfunction and neurodegeneration. The brain's vulnerability to oxidative stress (OS) is considered a crucial detrimental factor in Alzheimer's disease. OS and Aβ are linked to each other because Aβ induces OS, and OS increases the Aβ deposition. Thus, the answer to the question "which comes first: the chicken or the egg?" remains extremely difficult. In any case, the evidence for the primary occurrence of oxidative stress in AD is attractive. Thus, evidence indicates that a long period of gradual oxidative damage accumulation precedes and results in the appearance of clinical and pathological AD symptoms, including Aβ deposition, neurofibrillary tangle formation, metabolic dysfunction, and cognitive decline. Moreover, oxidative stress plays a crucial role in the pathogenesis of many risk factors for AD. Alzheimer's disease begins many years before its symptoms, and antioxidant treatment can be an important therapeutic target for attacking the disease.

Citing Articles

Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications.

Dash U, Bhol N, Swain S, Samal R, Nayak P, Raina V Acta Pharm Sin B. 2025; 15(1):15-34.

PMID: 40041912 PMC: 11873663. DOI: 10.1016/j.apsb.2024.10.004.


Effect of N-Acetyl Cysteine as an Adjuvant Treatment in Alzheimer's Disease.

Lomeli Martinez S, Pacheco Moises F, Bitzer-Quintero O, Ramirez-Jirano J, Delgado-Lara D, Cortes Trujillo I Brain Sci. 2025; 15(2).

PMID: 40002497 PMC: 11852533. DOI: 10.3390/brainsci15020164.


The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization.

Leisgang Osse A, Kinney J, Cummings J Alzheimers Dement (N Y). 2025; 11(1):e70050.

PMID: 39935614 PMC: 11812129. DOI: 10.1002/trc2.70050.


Interplay between oxidative stress, neuroinflammatory cytokines and melatonin in Alzheimer's disease: Insights from cerebrospinal fluid analysis.

Artime-Naveda F, Hevia D, Alonso-Arias R, Martinez C, Quiros-Gonzalez I, Cernuda-Cernuda R Heliyon. 2025; 11(2):e41841.

PMID: 39897852 PMC: 11786639. DOI: 10.1016/j.heliyon.2025.e41841.


Reactive Oxygen Species, a Potential Therapeutic Target for Vascular Dementia.

White A, Talkington G, Ouvrier B, Ismael S, Solch-Ottaiano R, Bix G Biomolecules. 2025; 15(1).

PMID: 39858401 PMC: 11761268. DOI: 10.3390/biom15010006.


References
1.
Peers C, Pearson H, Boyle J . Hypoxia and Alzheimer's disease. Essays Biochem. 2007; 43:153-64. DOI: 10.1042/BSE0430153. View

2.
Behl T, Kaur I, Fratila O, Brata R, Bungau S . Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease. Int J Mol Sci. 2020; 21(20). PMC: 7589257. DOI: 10.3390/ijms21207443. View

3.
Li S, Jin M, Liu L, Dang Y, Ostaszewski B, Selkoe D . Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease. Acta Neuropathol Commun. 2018; 6(1):121. PMC: 6225562. DOI: 10.1186/s40478-018-0626-x. View

4.
Mendez M . Early-Onset Alzheimer Disease. Neurol Clin. 2017; 35(2):263-281. PMC: 5407192. DOI: 10.1016/j.ncl.2017.01.005. View

5.
Xu J, Guo S, Xue R, Xiao L, Kou J, Liu Y . Adalimumab ameliorates memory impairments and neuroinflammation in chronic cerebral hypoperfusion rats. Aging (Albany NY). 2021; 13(10):14001-14014. PMC: 8202885. DOI: 10.18632/aging.203009. View